Inside the Islet Exploring Issues in Type 2 Diabetes Role of Pancreatic Islets in Maintaining Normal Glucose Homeostasis.

Slides:



Advertisements
Similar presentations
Role of Amylin and Glucagon in Postprandial Glycemic Excursions in Pediatric Type 1 Diabetes. Rubina Heptulla MD, Luisa M. Rodriguez MD and Morey W. Haymond.
Advertisements

1,5 Anhydroglucitol and the Monitoring of Postprandial Glucose Control Steven D Wittlin M.D. U of Rochester School of Medicine and Dentistry.
$100 $400 $300$200$400 $200$100$100$400 $200$200$500 $500$300 $200$500 $100$300$100$300 $500$300$400$400$500.
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200.
Category 1 Category 2 Category 3 Category 4 Category.
Category Category Category Category Category.
$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.
Who Wants To Be A Millionaire?
£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.

Volatilization of PAHs from sealcoated pavement Peter C. Van Metre, Barbara J. Mahler, William Foreman, Christopher Braun, Jennifer Wilson, Teresa Burbank,
Category Heading Category Heading Category Heading.
CV Health: Three Ways to ‘kNOw’
Current Management of Type 1 and Type 2 Diabetes Thomas Donner, M.D. Division of Endocrinology & Metabolism.
GLP-1 Receptor Agonists: Emerging Treatments in Diabetes Therapeutics
Homeostasis Maintainingan Internal Balance. Homeostasis The property of a system, either open or closed, that regulates its internal environment so as.
What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.
Clinical Presentation of Type 2 Diabetes 1. Risk Factors for Prediabetes and Type 2 Diabetes Family history of diabetes mellitus Cardiovascular disease.
It all began in 1983…  A group in Sweden noticed that there were differenced in blood glucose and insulin levels in patients with AD.  Bucht 1983 Changes.
Type 2 Diabetes: Pathophysiology and Opportunities for Treatment
Endocrine & Cell Communication Part IV:
Interactions between the Liver and Pancreas. Explain the control of blood glucose concentration, including the roles of glucagon, insulin and α and β.
Conditions associated with insulin resistance
Jovonne Carr Cheyenne Hockenhull
Chapter 13 Disorders of the Pancreas
Control of blood sugar.
Insulin Pump Debrief. Now that you have worn a Pump… FAQ from people with diabetes Where do I wear this thing? What do I do with it when I play sports?
PANCREAS Objectives The students should be able to describe: 1. The endocrine part of the pancreas within the exocrine portion. 2. The histological features.
Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:
GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.
1QQ # 4 Name on top edge, back side of paper Answer on blank side of paper. Answer one of the following: 1. Why is light colored, loose fitting clothing.
The Pancreas by esi & luke.. An Introduction to the Pancreas  Location → The pancreas is located deep within the abdomen of the body, beneath the liver.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Part 4.
Part 6.
1 ENDOCRINE & CELL COMMUNICATION PART IV: MAINTAINING BALANCE (HOMEOSTASIS)
Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose Diabetes Division and the Clinical.
Glucose Metabolism Dr Lenon T Gwaunza MBChB, BSc (Hons), MSc (UCL)
Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?
What is Microvascular Disease?
Percentile lines for the relationship between insulin sensitivity (SI) and the first-phase insulin response (AIRglucose) based on data from 93 normal subjects.45.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
The Endocrine System Pancreatic Islets
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Mean rates of insulin and glucagon delivery from an artificial pancreas at various blood glucose levels. The device was programmed to establish and maintain.
Homeostasis: Control of blood glucose
How the pancreas controls blood sugar levels
Type 1 Diabetes Mellitus
Diabetes and Bone: the model of GIO
The Pancreas.
Glucose homeostasis: roles of insulin and glucagon. 1A.
Figure 2 Evidence for the incretin effect and
Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Relationship between plasma glucose, insulin and glucagon levels
GLP-1 Agonists and DPP-4 Inhibitors How do they work?
Carbohydrate absorption inhibitors α-glucosidose inhibitors
Incretin Physiology in Type 2 Diabetes Mellitus
The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.
Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.
Comparison of the regression lines for AIRarg (the acute insulin response to intravenous arginine over 2–5 min after injection) and AIRargMAX (the response.
Somatostatin released by δ-cells exerts a tonic inhibition on glucagon and insulin secretion but is not required for the glucagonostatic effect of glucose.
Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.
Model for central nervous system regulation of insulin secretion and insulin sensitivity via the SNS during cold exposure. Model for central nervous system.
Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,
Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.
The Insulin Receptor Talks to Glucagon?
(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.
Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.
Presentation transcript:

Inside the Islet Exploring Issues in Type 2 Diabetes Role of Pancreatic Islets in Maintaining Normal Glucose Homeostasis

Learning Objectives After participating in this educational activity, you will be able to: Describe the role of islet cells ( and β) in maintaining normal glucose homeostasis. Understand disturbances in β-cell function, glucagon secretion, and hepatic glucose production in type 2 diabetes. Describe the progressive nature of β-cell dysfunction and its role in the pathogenesis of type 2 diabetes.

- and -Cells in the Pancreas of Normal Individuals Produce glucagon 1 Produce insulin and amylin 3 Glucagon released in response to low blood glucose levels 1 Insulin released in response to elevated blood glucose levels 1 Comprise about 15% of the endocrine mass of the pancreas 1 Comprise about 70%–80% of the endocrine mass of the pancreas 1,2 Located in the periphery of the islet 1 Located in the central portion of the islet 1,2 -Cells 1. Cleaver O et al. In: Joslins Diabetes Mellitus. Lippincott Williams & Wilkins; 2005:21– Rhodes CJ. Science. 2005;307:380– Kahn SE et al. Diabetes. 1998;47:640–645.

N=11. Adapted with permission from Woerle HJ et al. Am J Physiol Endocrinol Metab. 2003;284:E716–E725. Insulin Increases and Glucagon Falls in Response to Meals in Normal Subjects Minutes After Meal Ingestion – mg/dL ( - ) Glucose pM ( - ) Insulin ng/L ( - ) Glucagon

The Normal β-Cell Insulin Response to Intravenous (IV) Glucose Is Biphasic 2nd phase N=17 subjects. Hyperglycemic clamp technique was used. Adapted with permission from Pratley RE et al. Diabetologia. 2001;44:929–945. © Springer-Verlag, Time, min Plasma Insulin, pmol/L 1st phase

Relationship Between Insulin Sensitivity and Insulin Response in Apparently Healthy Subjects Men Women 2,000 1,500 1, th 50th 5th AIRglucose=first-phase insulin response. Insulin response examined following intravenous administration of glucose. N=93 apparently healthy subjects aged <45 yrs. Adapted from Vidal J, Kahn SE. In: Genetics of Diabetes Mellitus. Kluwer Academic Publishers; 2001;109–131. Figure 2. With kind permission from Springer Science and Business Media. AIRglucose, pM Insulin Sensitivity Index, S i x 10 –5 min –1 /pM

Compensatory β-Cell Insulin Secretion With Increasing Insulin Resistance 95th 50th 5th In subjects without diabetes, insulin secretion is modulated by the prevailing degree of insulin sensitivity. For glucose tolerance to remain constant when insulin sensitivity varies, a proportionate and reciprocal alteration in insulin output has to occur. AIRmax=measure of the β-cell secretory capacity. β-cell secretory capacity to nonglucose secretagogue arginine was used to characterize the relation between insulin release and glucose level. N=43 subjects with varying degrees of obesity, aged <45 years, fasting plasma glucose <115.2 mg/dL. Adapted from Kahn SE et al. Diabetes. 1993;42:1663–1672. Modified with permission from The American Diabetes Association. Copyright © 1993 American Diabetes Association. 0 1,000 2,000 3,000 4,000 5, AIRmax, pM Men Women Insulin Sensitivity Index, S i x 10 –5 min –1 /pM

Net Hepatic Glucose Output, µmoL kg –1 min –1 Hepatic Sinusoidal Insulin, pmol/L Net Hepatic Glucose Output, µmoL kg –1 min –1 Hepatic Sinusoidal Glucagon, ng/L Experiment carried out in overnight fasted conscious dogs. Adapted from Cherrington AD. Copyright © 1999 American Diabetes Association. From Diabetes, 1999;48:1198– Reprinted with permission from The American Diabetes Association. Insulin vs Net Hepatic Glucose Output Glucagon vs Net Hepatic Glucose Output Fixed basal glucagon level Hepatic Glucose Production in Dogs Is Regulated by Insulin and Glucagon Fixed basal insulin level

Insulin and Glucagon Regulate Normal Glucose Homeostasis Glucose output Glucose uptake Glucagon (α-cell) Insulin (β-cell) Pancreas LiverMuscle Porte D Jr et al. Clin Invest Med. 1995;18:247–254. Adapted with permission from Kahn CR, Saltiel AR. Joslins Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins; 2005:145–168. Blood glucose

Role of Selected Organs in Normal Glucose Homeostasis Glucagon Fat Plasma Glucose Pancreas Liver α β Adapted with permission from Kahn CR, Saltiel AR. Joslins Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins; 2005:145–168. Brain Muscle Insulin Insulin-dependent glucose uptake Insulin Insulin-independent glucose uptake

Summary: Normal Glucose Homeostasis Involves Pancreatic Islet Cells in Normal Subjects Insulin from β-cells Blood glucose homeostasis Ingestion of food Pancreas -cells Glucagon from α-cells Glucose production by liver Glucose uptake by adipose and muscle tissue Release of gut hormones GI tract Glucose dependent

Summary of the Role of the Pancreatic Islet in Normal Glucose Homeostasis Pancreatic α- and β-cells play several key roles in maintaining normal glucose homeostasis by regulating insulin and glucagon. 1 The normal β-cell insulin response is biphasic, with a first (early) phase and a second (late) phase. 2 In response to glucose loading, insulin levels increase and glucagon levels fall to maintain normal glucose homeostasis. 3 To maintain normal glucose homeostasis, any change in insulin sensitivity is balanced by a reciprocal and proportionate change in β-cell function Porte D Jr, Kahn SE. Clin Invest Med. 1995;18:247– Pratley RE, Weyer C. Diabetologia. 2001;44:929– Woerle HJ et al. Am J Physiol Endocrinol Metab. 2003;284:E716–E Kahn SE et al. Diabetes. 1993;42:1663–1672.

Islet Cell Dysfunction and Abnormal Glucose Homeostasis in Type 2 Diabetes

Glucose output Glucose uptake Glucagon (α-cell) Insulin (β-cell) Pancreas Liver Hyperglycemia Muscle Islet cell dysfunction 1. Del Prato S, Marchetti P. Horm Metab Res. 2004;36:775– Porte D Jr, Kahn SE. Clin Invest Med. 1995;18:247–254. Adapted with permission from Kahn CR, Saltiel AR. Joslins Diabetes Mellitus. 14th ed. Lippincott Williams & Wilkins; 2005:145–168. The Pathophysiology of Type 2 Diabetes Includes Islet Cell Dysfunction and Insulin Resistance 1,2 * *Reduced effect of insulin indicating insulin resistance

First-Phase Insulin Response to IV Glucose Is Lost in Type 2 Diabetes Normal Type 2 Diabetes n=9 normal; n=9 type 2 diabetes. Adapted from Pfeifer MA et al. Am J Med. 1981;70:579–588. With permission from Excerpta Medica, Inc – Time, min – Time, min Plasma Insulin, µU/mL

Some Abnormalities of β-Cell Function in Type 2 Diabetes Disrupted pulsatile insulin response 1 proinsulin/insulin ratio 1 β-cell responsiveness to glucose 2,3 insulin production 4 – insulin – insulin granules β-Cell dysfunction 1. Buchanan TA. Clin Ther. 2003;25(suppl B):B32–B Buse JB et al. In: Larsen PR et al. Williams Textbook of Endocrinology. 10th ed. Saunders; 2003;1427– Ward WK et al. J Clin Invest. 1984;74:1318– Marchetti P et al. J Clin Endocrinol Metab. 2004;89:5535–5541.

Patients With Type 2 Diabetes Have Decreased β-Cell Responsiveness to Glucose n=11 control; n=11 type 2 diabetes. ISR=insulin secretory rate; BMI=body mass index. Adapted with permission from Byrne MM et al. Am J Physiol Endocrinol Metab. 1996;270:E572–E579. Type 2 diabetes Control Glucose, mg/dL ISR/BMI, pmol x m 2 /(min x kg)

N=277 Pima Indians; NGT=normal glucose tolerance; IGT=impaired glucose tolerance; T2DM=type 2 diabetes; EMBS=estimated metabolic body size. Changes in β-cell function, measured as acute insulin response to glucose (AIRglucose) relative to changes in insulin sensitivity, measured by clamp technique at a low insulin concentration (M-low). Adapted with permission from Weyer C et al. J Clin Invest. 1999;104;787–794. AIRglucose, μU/mL M-Low, mg/kg EMBS/min T2DM IGT NGT Nonprogressors Progressors The Relationship Between Insulin Secretion and Insulin Action During the Development of Type 2 Diabetes

Insulin and Glucagon Dynamics in Response to Meals Are Abnormal in Type 2 Diabetes – Glucose, mg % Insulin, μ/mL Glucagon, μμ/mL Meal (minutes) Type 2 diabetes Normal patients n=12 normal; n=12 type 2 diabetes. Adapted with permission in 2005 from Müller WA et al. N Engl J Med. 1970;283:109–115. Copyright © 1970 Massachusetts Medical Society. All rights reserved.

P<0.001 Fasting Fasting and Postprandial Glucagon Levels Are Elevated in Patients With Impaired Glucose Intolerance and Type 2 Diabetes P<0.001 Postprandial NGT=normal glucose tolerance, n=33; IGT=impaired glucose tolerance, n=15; T2DM=type 2 diabetes mellitus, n=54. Toft-Nielson M-B et al. J Clin Endocrinol Metab. 2001;86:3717–3723. Fasting Plasma Glucagon, pmol/LPostprandial Glucagon at 240 min, pmol/L

Lack of Suppression of Glucagon Causes Postprandial Hyperglycemia in Type 2 Diabetes * – Time, min Glucose, mg/dL Nonsuppressed glucagon Suppressed glucagon *P< N=9 (7 men, 2 women). Reprinted with permission from Shah P et al. J Clin Endocrinol Metab. 2000;85:4053–4059. Copyright © 2000, The Endocrine Society.

The abnormalities in β-cell function typically include: A.Decreased insulin production and increased proinsulin/insulin ratio B.Abnormal pulsatile insulin response C.Decreased β-cell responsiveness to glucose D.All of the above What Are the Abnormalities in β-Cell Function Seen in Type 2 Diabetes?

Summary of Islet Cell Dysfunction and Abnormal Glucose Homeostasis in Type 2 Diabetes Islet cell dysfunction and insulin resistance play important roles in the pathophysiology of type 2 diabetes. 1 In type 2 diabetes: –First-phase insulin response by β-cells is lost. 2 –There is abnormal β-cell function and decreased β-cell responsiveness to glucose. 3 –Endogenous glucose production is elevated. 4 –Fasting and postprandial glucagon secretion are elevated. 4,5 1. Del Prato S, Marchetti P. Horm Metab Res. 2004;36:775– Ward WK et al. Diabetes Care. 1984;7:491– Kahn SE. Diabetologia. 2003;46:3– Basu A et al. J Invest Med. 2004;52:366– Toft-Nielsen M-B et al. J Clin Endocrinol Metab. 2001;86:3717–3723.

The Development and Progression of Type 2 Diabetes

Patients at High Risk of Type 2 Diabetes Have Inadequate β-Cell Compensation for Degree of Insulin Resistance Type 2 diabetes Older subjects IGT AIRglucose, pmol/L Insulin Sensitivity Index, S i x 10 –5 min –1 /pmol/L 75th 50th 25th 5th Relatives of type 2 diabetes IGT=Impaired glucose tolerance, n=21; type 2 diabetes, n=10; older subjects, n=13; relatives, n=14. Percentile lines based on data from 93 healthy subjects. AIRglucose=first-phase insulin response. Adapted from Vidal J, Kahn SE. In: Genetics of Diabetes Mellitus. Kluwer Academic Publishers; 2001;109–131. Figure 3. With kind permission from Springer Science and Business Media.

Inadequate Insulin Secretion and Insulin Action Occur Early in the Development of Type 2 Diabetes AIRglucose=acute insulin response; M-high=maximally insulin-stimulated glucose disposal. *P<0.05; **P<0.01. Adapted with permission from Weyer C et al. J Clin Invest. 1999;104:787– NGT AIRglucose, µ/mL IGTT2DM Overall Time Effect P< NGT M-High, mg/kg EMBS/min IGTT2DM Overall Time Effect P< * ** Longitudinal study over 5.1 ± 1.4 years; N=17 Pima Indians in whom glucose tolerance deteriorated from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) to type 2 diabetes (T2DM).

HOMA % B Years From Diagnosis HOMA % S β-Cell FunctionInsulin Sensitivity HOMA=Homeostasis Model Assessment; HOMA % B=β-cell function; HOMA % S=Insulin sensitivity. N= year follow-up of the Belfast Diet Study. Data from Group 2 shown: newly diagnosed T2DM subjects who required additional treatment (due to secondary failure to diet therapy) at 5–7 years. Reproduced with permission from Levy J et al. Diabet Med. 1998;15:290–296. © 1998 Blackwell Publishing. -Cell Function Declines After Diagnosis, Whereas Insulin Sensitivity Remains Relatively Stable Years From Diagnosis

Years A1C, % Diet/conv Rx (n=297) Metformin (n=251) SU/intensive (n=695) Years Progressive Impairment of -Cell Function and Deterioration of Glycemic Control in Type 2 Diabetes -Cell Function Declines Over Time -Cell function, % β Diet/conv Rx (n=376) Metformin (n=159) SU/intensive (n=511) A1C Increases Over Time Diet/conv Rx=conventional therapy (diet alone); UKPDS=United Kingdom Prospective Diabetes Study; SU/intensive=sulfonylurea or insulin. N=4,209 newly diagnosed patients with type 2 diabetes. Reprinted from UK Prospective Diabetes Study Group 16. Copyright © 1995 American Diabetes Association. From Diabetes. 1995;44:1249–1258. Reprinted with permission from The American Diabetes Association.

What Are Some Determinants of -Cell Mass? Some determinants of -cell mass include: A.Cell proliferation rate B.Rate of cell death (apoptosis) C.Regeneration of β-cells (neogenesis) D.All

Some β-Cell Abnormalities in Type 2 Diabetes -cell mass 1,2 -cell apoptosis 1 Impaired β-cell proliferation 2,3 Impaired β-cell neogenesis 2,3 β-Cell abnormalities 1. Butler AE et al. Diabetes. 2003;52:102– Donath MY, Halban PA. Diabetologia. 2004;47:581– Rhodes CJ. Science. 2005;307:380–384.

Inside the Islet: Exploring Issues in Type 2 Diabetes In summary: The pathophysiology of type 2 diabetes includes islet cell dysfunction, insulin resistance, and increased hepatic glucose output. 1–3 Elevated hepatic glucose production in type 2 diabetes results from the combination of excess glucagon and diminished insulin. 1 Early and progressive β-cell dysfunction is integral to the development of type 2 diabetes and to the deterioration of glucose control over time Porte D Jr, Kahn SE. Clin Invest Med. 1995;18:247– Del Prato S, Marchetti P. Horm Metab Res. 2004;36:775– Del Prato S, Marchetti P. Diabetes Technol Ther. 2004;6:719–731. © 2006 Merck & Co., Inc. All rights reserved (1)-01/06-JAN.